CompanyQURENasdaqAmsterdam

uniQure N.V.

uniQure develops gene therapies for severe genetic diseases.

SEC EDGAR ClinicalTrials.gov uniqure.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

uniQure reports 48-month AMT-130 data for Huntington's disease gene therapy

Sep 29Clinical readoutuniQure N.V.

uniQure files BLA and UK MAA for Huntington's gene therapy AMT-130

Sep 2Regulatory decisionuniQure N.V.

July 2026

uniQure reaffirms Q3 2026 BLA plans for AMT-130 in Huntington's disease

Jul 29Quarterly updateuniQure N.V.